← brief for 2026-08-14 · Slowing decline

Beyond current standards: combination therapy and emerging targets in diabetic kidney disease.

Article B Peer reviewed Small trial

Key takeaways

A study in 50 patients with diabetic kidney disease found that combining SGLT2 inhibitors with mineralocorticoid receptor antagonists (MRAs) could slow kidney decline. The study lasted 2 years.

Who did this work

Lee J · Yu MY · Korean Diabetic Kidney Disease Study Group

Source

Article · PubMed, the drug frontier · 2026 Aug 13
https://pubmed.ncbi.nlm.nih.gov/42595707/